Bayer Aktiengesellschaft (BAYRY)
| Market Cap | 30.53B |
| Revenue (ttm) | 51.10B |
| Net Income (ttm) | -3.39B |
| Shares Out | 3.93B |
| EPS (ttm) | -3.45 |
| PE Ratio | n/a |
| Forward PE | 1.46 |
| Dividend | $0.03 (0.38%) |
| Ex-Dividend Date | Apr 29, 2024 |
| Volume | 1,427,535 |
| Open | 7.80 |
| Previous Close | 8.02 |
| Day's Range | 7.77 - 7.85 |
| 52-Week Range | 6.96 - 14.90 |
| Beta | 0.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 27, 2024 |
About BAYRY
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter med... [Read more]
News
Bayer presents latest data from oncology portfolio at 2024 ASCO Annual Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from Ma...
Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of dosing in a Phase I first-in-human clinical study with 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy. The inv...
Bayer's Q1 adjusted profit beats analyst consensus
Bayer on Tuesday reported a 1.3% decline in adjusted earnings in the first quarter, beating analysts' forecasts on better-than-expected performance at its prescription drugs and agriculture divisions.
Study Design and Baseline Characteristics of Prespecified, Exploratory Pooled Analysis to Investigate Effect of Finerenone on Cardio-Kidney Outcomes in Patients with CKD and Type 2 Diabetes and/or Heart Failure Shared at Heart Failure 2024 Congress
WHIPPANY, N.J.--(BUSINESS WIRE)--The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone1, were presented...
Bayer to Present Investigational Data from Comprehensive KERENDIA® (finerenone) Clinical Trial Program at Heart Failure 2024 Congress
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present Kerendia® (finerenone) data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in...
WomenHeart and Bayer Join Forces to Enhance Heart Health Awareness and Education Among Women Across the U.S.
WASHINGTON--(BUSINESS WIRE)--WomenHeart: The National Coalition for Women with Heart Disease, in collaboration with Bayer, is proud to announce the launch of the Understanding Her Heart: Women and Car...
Bayer to unveil late-breaking data from Phase III OASIS 1 and 2 for elinzanetant in the treatment of vasomotor symptoms associated with menopause
BERLIN--(BUSINESS WIRE)--Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, evaluating the efficacy and safety of the investigational compound elinzanetant versus pl...
FourKites, Bayer and Graphic Packaging International to Present at Gartner Supply Chain Symposium/Xpo 2024
CHICAGO--(BUSINESS WIRE)--Leading real-time supply chain visibility provider FourKites today announced that it will join Bayer and Graphic Packaging International in two separate tracks at the upcomin...
Bayer and Evotec Collaborate to Advance Precision Cardiology
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS J...
Bayer CEO wins first AGM shareholder vote
Bayer CEO Bill Anderson on Friday won a vote of confidence at his first annual general meeting (AGM) at the helm of the embattled healthcare and agriculture group, defying a challenge from one German ...
Bayer investor Deka takes a stand against CEO in annual vote
Bayer shareholder Deka Investment said on Friday it would not join other large investors in supporting the healthcare and agriculture group's management at its annual general meeting.
Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues.
Bayer confirms outlook despite slow businesses in agriculture, consumer health
Bayer on Monday confirmed its full-year guidance for earnings and cash flow despite slow business at its crop science and consumer health divisions.
Bayer's patent for blood thinner Xarelto invalid, UK court rules
Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker.
Bayer and Google Cloud to accelerate development of AI-powered healthcare applications for radiologists
LAS VEGAS--(BUSINESS WIRE)--Bayer and Google Cloud today announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve pati...
Bayer's Consumer Health Division Announces Changes to North America Leadership Team
WHIPPANY, N.J.--(BUSINESS WIRE)--Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America. She will report directly to Dave Toma...
Google partners with Bayer on new AI product for radiologists
Google Cloud and Bayer are building a new AI-powered platform to help radiologists work more efficiently.
Judge slashes Bayer $1.56 billion Roundup verdict to $611 million
A Missouri judge slashed a $1.56 billion verdict against Bayer to $611 million for three people who claimed its Roundup weed killer caused their cancer, by reducing punitive damages. Bayer said on Fri...
Federman & Sherwood Investigates Bayer Heritage Federal Credit Union for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Bayer Heritage Federal Credit Union for Data Breach.
Bayer Appoints Sue Ann Pentecost as Vice President, Head of U.S. Pharmaceutical Communications
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced Sue Ann Pentecost as the new Vice President, Head of Pharmaceuticals Communications in the United States. She will report directly to Beth Roden,...
Bayer says 2024 sales of prostate cancer drug above $1 bln
Bayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti...
Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines
BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CD...
Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth
BERLIN--(BUSINESS WIRE)--Bayer's Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused. The com...
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. The...
Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer's elinzanetant
BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus ...